India s drug regulator on Thursday granted regular market approval for COVID-19 vaccines Covishield and Covaxin for use in the adult population subject to certain conditions, official sources said. The approval was granted under the New Drugs and Clinical Trials Rules, 2019. Under the conditions, the firms shall submit data of ongoing clinical trials and the vaccines to be supplied for programmatic setting. Adverse event following immunisation will continue to be monitored. The Drugs Controller
The government Friday said there is no need to panic on the need for an immediate change in the dosage interval of Covishield vaccine, underlining that reducing the time gap requires proper scientific study in the Indian scenario.
URL copied
Covishield s first dose develops strong immunity than Covaxin s: ICMR head
The government recently accepted the Covid-19 Working Group s recommendation for extending the gap between the two doses of the Covishield vaccine from 6-8 weeks to 12-16 weeks. However, the dosage interval for Covaxin has been left unchanged and remains four weeks.
The decision to increase the interval between two doses of Covishield was taken because the first dose of Covishield can develop a strong immunity.Â
According to Indian Council of Medical Research (ICMR) head Dr Balram Bhargava, the immunity after the first dose of Covishield was found to be strong and that the three months gap will give the best results, a report in Times of India said.
Amid multiple states reporting a shortage of COVID-19 vaccine, Serum Institute and Bharat Biotech have submitted to the Centre their production plan for the next four months, informing they can ramp it up to 10 crore and 7.8 crore doses respectively by August, official sources said on Wednesday
Serum Institute slashes prices of Covishield for states to Rs 300 per dose
Serum Institute slashes prices of Covishield for states to Rs 300 per dose
Doses of its Covid-19 vaccine Covishield will be made available to states at a price of Rs 300 per dose, Serum Institute of India CEO Adar Poonawalla said in a tweet on Wednesday. This is
advertisement
Employees pack boxes containing vials of Covishield at Serum Institute in Pune (Photo Credits: AP)
HIGHLIGHTS
Serum Institute has received orders for 340 million doses from states
Covishield the most affordable Covid-19 vaccine in the market, SII had said
Adar Poonawalla, CEO of Pune-based Serum Institute of India, said Covishield will be made available to states at a price of Rs 300 per dose. SII, which is producing University of Oxford and AstraZeneca s Covid-19 vaccine, had earlier priced the doses at Rs 400 for states.